Bio-Path Holdings

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Path Holdings reports positive Q1 results and advances key drug programs

Bio-Path Holdings (BPTH) showcased progress in key drug programs, financial stability, and global patent expansion. While facing regulatory and competitive challenges, the company is well-positioned to capitalize on opportunities in the biopharmaceutical sector. Optimism for future growth and innovation was expressed by CEO Peter Nielsen during the earnings call.

Bio-Path reports Q2 progress with prexigebersen and promising trials

Bio-Path Holdings showcased progress in clinical trials and financial management, emphasizing innovation and commitment to revolutionize cancer treatment.
While facing challenges in commercialization and market competition, the company's strong dedication to personalized medicine and promising trial results present growth opportunities.
With a focus on leveraging molecular biomarkers and advancing pipeline candidates, Bio-Path is strategically positioned to drive future success in the oncology space.

Bio-Path advances clinical trials, faces financial challenges, eyes growth

Bio-Path Holdings showcased progress in clinical trials targeting proteins in cancer and metabolic diseases, despite a net loss in Q3 2024.
The company's innovative approach and focus on treatment efficacy position it well for future growth and potential partnerships.
While facing financial challenges, Bio-Path's expansion into new therapeutic areas and optimistic outlook signal opportunities for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Brings 25 Years of Experience in Business Development and Marketing Brings 25 Years of Experience in Business Development and Marketing

Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors

HOUSTON, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 3:25 p.m. ET in New York.

Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference

HOUSTON, Aug.  26, 2019  (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced patient dosing in Bio-Path’s amended Phase 2 trial of prexigebersen for the treatment of acute myeloid leukemia (AML), as announced in March 2019.

Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2019 Results - Earnings Call Transcript

Bio-Path rocketed Monday after withdrawing its December offering for stocks and warrants. Bio-Path is working on a number of cancer treatments.

How This Highly Rated Biotech Stock Added To Its Meteoric Run

Bio-Path Holdings Inc.'s stock rocketed 48% in morning trade Monday, after the biotechnology company focused on cancer treatments filed to withdraw a common stock offering.

Bio-Path's stock rockets after withdrawal of stock offering

Bio-Path Holdings (BPTH) CEO, Peter Nielsen on Q4 2018 Results - Earnings Call Transcript

Bio-Path Holdings Inc. (NASDAQ: BPTH) shares are on a rampage, with its second day of more than doubling. Shares actually were halted at multiple points during the day for volatility spikes.

Bio-Path Shares on the Warpath

Bio-Path Holdings Inc (BPTH) shares are on a tear, advancing over 160 percent on roughly 37 times their average volume Wednesday and trading up more than 200 percent Thursday afternoon.

Bio-Path Jumps Nearly 600% In 2 Days: What You Need To Know

News for Bio-Path Holdings Stock (BPTH)